Research at Boston Children's Hospital

The research enterprise at Boston Children’s Hospital, comprising more than 3,000 researchers, is the world’s largest at a pediatric center. Our work is fueled by a deep understanding of disease biology coupled with world-class discovery platforms, including genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, biobanks, disease-specific stem cell lines, and a range of animal models. We have special expertise in rare disease discovery, a robust Translational Research Program and large, diverse patient populations for clinical research and trials.

More than 3,000 researchers and scientific staff

research space

1 million square feet of research space — and growing

Boston Children's research funding

$423 million in research funding in FY2020 — #1 in NIH funding for pediatric research

Boston Children's Journal articles

3,400 articles/year in peer reviewed journals — the most of any pediatric hospital

Boston Children's inventions

149 new inventions in FY2020 alone

iPSC derived airway infected with SARS-CoV-2. Image: Ruobing Wang, Boston Children’s Hospital

COVID-19 Research

As of March 2021, Boston Children’s Hospital had produced 1,127 COVID-19-related research publications, according to Erudera. These range from molecular investigations of SARS-CoV-2 and the immune response to large-scale clinical studies of the effects of COVID-19 in children.


Research Highlights

GlycoRNA graphic

Glycosylated RNAs upend cell biology as we know it

Ryan Flynn, MD, PhD, a new investigator in our Stem Cell program, has discovered a new category of sugar-coated molecules that ride on our cells. His groundbreaking work should open multiple research avenues in immunology and beyond.

Preterm infant microbiome illustration

Piecing together the preterm infant microbiome

Understanding how the microbiome forms in preterm infants is essential to knowing how to intervene to protect their future health, says Seth Rakoff-Nahoum, MD, PhD. He tracks how microbes plant their flags in this nearly pristine environment.
Neural stem cells illustration

Recommendations for reproducibility in stem cell research

Lab research on intellectual and developmental disabilities often uses induced pluripotent stem cells differentiated into neural cells. But lab to lab variation makes results hard to reproduce. Mustafa Sahin, MD, PhD, et al. aim to provide consistency, speeding research progress.

An image worth 1,000 words?

The 2021 Science Media Exhibition solicited more than 40 science image submissions from research laboratories and programs throughout Boston Children’s Hospital. The images here were presented live during a virtual event held in June in conjunction with Dr. M. Judah Folkman Research Day.

Follow us on Twitter

BCH Innovation News @BCH_Innovation 9/27/2021 8:00:02 PM
It wasn’t until the late 1970s that solid laws were passed to reduce environmental #lead. Today, a large study in…
BCH Innovation News @BCH_Innovation 9/22/2021 7:00:02 PM
A new treatment for newborn seizures, developed by Dr. Janet Soul over the past decade, is tailored to newborns’ un…
BCH Innovation News @BCH_Innovation 9/22/2021 3:30:02 PM
A recent study in @TheLancet estimates that at least 104,884 U.S. children have lost one or both parents to #COVID…
BCH Innovation News @BCH_Innovation 9/20/2021 5:00:01 PM
Bridge-enhanced ACL repair (BEAR), a procedure pioneered by our Dr. Martha Murray, shows higher #patient outcome sc…
BCH Innovation News @BCH_Innovation 9/14/2021 7:00:01 PM
A pair of peptides on voltage-gated sodium channels act as receptors for site 1 channel blockers. Adding long hydro…
BCH Innovation News @BCH_Innovation 9/13/2021 9:00:01 PM
Novel #bioinspired anesthesia delivery system designed by Drs. Tianjiao Ji, Yang Li and Dan Kohane @BostonChildrens…
The commitment and compassion with which we care for all children and families is matched only by the pioneering spirit of discovery and innovation that drives us to think differently, to find answers, and to build a better tomorrow for children everywhere.

Kevin B. Churchwell, President and CEO